

## Correction: Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth

In this article (Cancer Res 2010;70:7800–9), which was published in the October 15, 2010 issue of *Cancer Research* (1), the legend for Fig. 2 is incomplete. The complete legend is provided below.

**Figure 2.** Dose titration of DT in DEREg mice defines functional depletion of Treg. Groups of 10 to 15 DEREg mice were inoculated s.c. with either  $3 \times 10^6$  EG7 lymphoma (A, C, E, G, and I) or  $1 \times 10^6$  MC38-OVA<sup>dim</sup> colon adenocarcinoma (B, D, F, H, and J) cells. Mice were treated with either PBS (A and B) or DT (1 ng, C and D; 10 ng, E and F; 100 ng, G and H; 1,000 ng, I and J) on day 0 (the day of tumor inoculation). Mice were then monitored for tumor growth every second day as described, and results were recorded as the tumor growth curves (size in cm<sup>2</sup>) of individual mice in each group. The number of cured mice is indicated in parentheses in each panel.

### Reference

1. Teng MW, Ngjow SF, von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. *Cancer Res* 2010;70:7800–9.

Published OnlineFirst 11/23/2010.

©2010 American Association for Cancer Research.

doi: 10.1158/0008-5472.CAN-10-3910